Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04520321 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/ Phase 2 Study of TTHX1114(NM141)
A Phase 1 study of Endothelial Dysfunction and Fuchs Endothelial Corneal Dystrophy, sponsored by Trefoil Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
- 8
- Study locations
NCT04520321 is a Phase 1 study of Endothelial Dysfunction and Fuchs Endothelial Corneal Dystrophy that has completed, run by Trefoil Therapeutics. The registered enrollment target is 22 participants, below the 92-participant average among 45 other Endothelial Dysfunction trials with a reported enrollment target (76% lower). The trial reports 8 study locations across 8 states.
The verdict
NCT04520321, a Phase 1 study of Endothelial Dysfunction and Fuchs Endothelial Corneal Dystrophy, has completed, sponsored by Trefoil Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
- 8
- Study locations
Study Summary
Prospective, multicenter, randomized, masked, vehicle-controlled, dose-escalation study
Conditions Studied
Interventions
- DRUG TTHX1114(NM141)
- OTHER Vehicle (placebo)
Study Locations (8)
California
- North Bay Eye Associates, Inc. - Petaluma
Florida
- Levenson Eye Associates, Inc - Jacksonville
Illinois
- Chicago Corneal Consultants - Hoffman Estates
Indiana
- Price Vision Group - Indianapolis
Missouri
- Tauber Eye Center - Kansas City
Nebraska
- Vance Thompson Vision - Omaha - Omaha
New York
- Alterman, Modi and Wolter - Poughkeepsie
South Dakota
- Vance Thompson Vision - Sioux Falls - Sioux Falls
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2020-08-19 |
| Est. Completion | 2021-05-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04520321
The ClinicalTrials.gov registry entry for NCT04520321 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 92-participant average among 45 other Endothelial Dysfunction trials with a reported enrollment target (76% lower). The listed sponsor is Trefoil Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Endothelial Dysfunction appearing as the primary indexed condition, and to 2 interventions - of which TTHX1114(NM141) is the first listed.
NCT04520321 reports 8 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT04520321 about?
NCT04520321 is a clinical study titled "A Phase 1/ Phase 2 Study of TTHX1114(NM141)". Prospective, multicenter, randomized, masked, vehicle-controlled, dose-escalation study
What is the current status of trial NCT04520321?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2020-08-19. Estimated completion is 2021-05-18.
What conditions does trial NCT04520321 study?
This clinical trial studies the following conditions: Endothelial Dysfunction, Fuchs Endothelial Corneal Dystrophy, Pseudophakic Bullous Keratopathy, Corneal Endothelial Dystrophy.
What interventions are being tested in trial NCT04520321?
The interventions under investigation include: TTHX1114(NM141) (DRUG), Vehicle (placebo) (OTHER).
Who is sponsoring clinical trial NCT04520321?
This trial is sponsored by Trefoil Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04520321 being conducted?
This trial has 8 study locations across California, Florida, Illinois, Indiana, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endothelial Dysfunction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes
RECRUITING · Phase 1
-
Effect of a Daily Supplement on Plasma PAI-1 Levels
RECRUITING · Phase 1
-
B-Complex: A Nutraceutical SANS Countermeasure
RECRUITING · Phase 1
-
Fisetin to Improve Vascular Function in Older Adults
ACTIVE NOT RECRUITING · Phase 1
-
Wild Blueberries and Cardiovascular Health in Middle-aged/Older Men and Postmenopausal Women
ACTIVE NOT RECRUITING · Phase 1
-
Enhancing Parasympathetic Activity to Improve Endothelial Dysfunction, Vascular Oxidative Stress in African Americans
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Endothelial Dysfunction
All registered trials for this condition
Fuchs Endothelial Corneal Dystrophy
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.